19 results
Original and Simplified PESI Prediction Rule Test Characteristics for 30-Day Mortality
#EBM #Diagnosis	#EM #IM #PCC	#PESI #sPESI #risk
and Simplified PESI ... Day Mortality #EBM ... #Diagnosis #EM ... #IM #PCC #PESI # ... sPESI #risk #score
Original and Simplified PESI PulmonaryEmbolism #Diagnosis #EM #IM #PCC #PESI #sPESI #risk #score #PE #Table
and Simplified PESI ... PulmonaryEmbolism #Diagnosis #EM ... #IM #PCC #PESI ... #sPESI #risk #score
Pulmonary Embolism Severeity Index - estimates 30d mortality #Diagnosis #Management #EM #IM #PCC #PESI #sPESI #risk
Diagnosis #Management #EM ... #IM #PCC #PESI ... #sPESI #risk #score
Pneumonia Severity Index (PSI) as a site-of-care tool. BUN, blood urea nitrogen; CHF, chronic heart failure;
Severity Index (PSI ... pressure #Management #EM ... #IM #Pneumonia ... Stratification #PSI
Pneumonia Severity Index (PSI) as a site-of-care tool. BUN, blood urea nitrogen; CHF, chronic heart failure;
Severity Index (PSI ... pressure #Management #EM ... #IM #Pneumonia ... Stratification #PSI
Common Causes of the Different Categories of Dizziness #Diagnosis #PrimaryCare #EM #IM #Differential #Dizziness #Vertigo #Disequilibrium
#PrimaryCare #EM ... #IM #Differential ... Lightheadedness #Table #NEJM
Pneumonia Severity Index (PSI)  - The PSI was developed from an administrative data set of
Severity Index (PSI ... ) - The PSI was ... populations #Management #EM ... #IM #Pneumonia ... Stratification #PSI
Pathogenesis of Nonalcoholic Steatohepatitis. Various factors, including inflammation, hyperinsulinemia or insulin resistance, and altered lipid homeostasis,
#Pathophysiology ... #GI #IM #NASH # ... NonAlcoholicFattyLiverDisease #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #Results #NEJM ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Adverse Events in the Safety Population, According
to Trial Group #EBM ... #Neuro #IM #Fremanezumab ... AdverseEvents #NEJM ... #NEJM